Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Almirall and BioFocus agree respiratory disease alliance

Almirall and BioFocus agree respiratory disease alliance

27th January 2012

Almirall has announced a new collaboration with BioFocus involving joint research into new treatments for respiratory disease.

A three-year agreement has been reached that will see BioFocus, an affiliate of the Galapagos healthcare group, apply its integrated drug discovery capabilities to deliver development candidates aimed at a key target specified by Almirall.

Potentially worth up to 7.5 million euros (6.27 million pounds), the deal will also utilise Almirall's expertise specific to the respiratory sector, which has been identified as a key area of focus by the company.

Dr Bertil Lindmark, chief scientific officer and executive director for research and development at Almirall, said: "We selected BioFocus for this alliance because of the excellent technology and scientific fit between both companies."

This comes on top of a previous arrangement between the two companies that was announced in November 2011, which will use BioFocus' screening technologies and compound collections in the development of respiratory and inflammatory disease treatments.ADNFCR-8000103-ID-801276551-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.